Login

Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Antibodies » Abs to Coagulation Factors » Anti -Factor XII (Hageman Factor)

Anti -Factor XII (Hageman Factor)

Pricing

  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.

Specifications

Clone Host Grade Applications
Polyclonal Goat Purified B
Human Factor XII (XII) (Hageman Factor) is a single chain (Mr=78,000) glycoprotein zymogen that circulates in plasma at a concentration of 40 mg/ml (1–5). Reciprical activation of XII to the active serine protease factor XIIa (XIIa) by kallikrein is central to initiation of the intrinsic coagulation pathway. Surface bound a-XIIa in turn activates factor XI to XIa. Secondary cleavage of a-XIIa by kallikrein yields b-XIIa, which catalyzes solution phase activation of kallikrein, factor VII and the classical complement cascade. The ability of a variety of negatively charged substances, both physiological and nonphysiological, to promote XII activation and, thus, initiation of the intrinsic pathway has led to the psuedonym “contact activation”. Binding to anionic surfaces induces a conformational change, making the XII zymogen more susceptible to cleavage by a variety of proteases (6,7). It is unlikely that binding to negatively charged surfaces alone is sufficient to activate XII, since highly purified preparations of XII and plasma deficient in prekallikrein and high molecular weight kininogen do not undergo this “autocatalysis” (8–11).
A single cleavage by kallikrein at R353-Val354 of XII yields a-XIIa, a 2 chain protease (Mr80,000) held together by disulfide bonds. The COOH-terminal light chain (Mr28,000) contains the catalytic triad (His-40, Asp-89, Ser-191), while the NH2-terminal heavy chain (Mr52,000) conatins the anionic surface binding portion of the molecule. A secondary cleavage of a-XIIa by kallikrein outside the disulfide bond yields b-XIIa (XIIf, BHFa, HFf, hageman factor fragments) (Mr28,000), which no longer binds anionic surfaces (12). b-XIIa can activate prekallikrein, but has little procoagulant activity (13,14).
Inhibitors of XIIa include C1-INH, a2-antiplasmin, a2-macroglobulin and antithrombin III. At physiological concentrations, the relative effectiveness of these inhibitors is 91: 4.5:3:1.5, respectively (10, 16–19). The ratio of C1-INH to XII has been implicated in the “cold activation” of factor VII and the conversion of prorenin to renin on storage of plasma (20,21).
Catalog #F0019
ApplicationsSuitable for use in Western Blot. Other applications have not been tested.
Recommended DilutionsOptimal dilutions to be determined by the researcher.
Storage and StabilityMay be stored at 4°C for short-term only. For long-term storage, store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Clone TypePolyclonal
IsotypeIgG
HostGoat
SourceHuman
Concentration~5mg/ml
FormSupplied as a liquid in 10mM HEPES, 150mM sodium chloride, pH 7.4, 50% glycerol.
PurityPurified.
ImmunogenHuman Factor XII
SpecificityRecognizes human Factor XII
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.


External Links